X0306 4 2021-04-27 0 0001357459 PALISADE BIO, INC. PALI 0001850265 Diaz Stephanie C/O PALISADE BIO, INC. 5800 ARMADA DR., SUITE 210 CARLSBAD CA 92008 1 0 0 0 Stock Option (Right to Buy) 41.20 2021-04-27 4 A 0 10203 A 2029-06-19 Common Stock 10203 10203 D Stock Option (Right to Buy) 26.85 2021-04-27 4 A 0 4406 A 2030-07-10 Common Stock 4406 4406 D The stock option vested in four equal quarterly installments from June 30, 2019. Received in exchange for a stock option to acquire 375,250 shares of common stock of Leading BioSciences, Inc. ("LBS") for $1.12 per share, pursuant to the Agreement and Plan of Merger, dated December 16, 2020, among Seneca Biopharma Inc., Townsgate Acquisition Sub 1, Inc. and LBS (the "Merger"). Per the terms of the Merger, each share of LBS's common stock was converted into the right to receive 0.02719 shares of Seneca's common stock. In the Merger, the name of the Issuer was changed from Seneca Biopharma, Inc. to Palisade Bio, Inc. The stock option vests according to the following schedule: 25% of the shares underlying the option vests on grant date and the remaining 75% vests in three equal quarterly installments thereafter beginning September 30, 2020. Received in the Merger in exchange for a stock option to acquire 162,069 shares of LBS common stock for $0.73 per share. /s/ JD Finley, Attorney-in-Fact for Stephanie Diaz 2021-04-29